Abstract: Provided herein are methods, and related compositions for identifying a putative essential gene which serves as an antibiotic target in a bacterium, the method, in some embodiments, comprising (a) generating an antibiotic resistant mutant of the bacterium by a method comprising the step of selecting for growth in the presence of an antibiotic to produce an antibiotic resistant mutant clone (AbR mutant); (b) transforming the AbR mutant with one or more essential genes of the bacterium and a transposon which insertionally inactivates bacterial DNA to produce a pool of transposon mutants which are merodiploid for the one or more essential genes; (c) growing bacteria from the merodiploid pool in the presence of different amounts of the antibiotic to produce two or more test cultures; and (d) comparing the distribution of transposon insertions between the test cultures to identify a putative essential gene serving as a target of the antibiotic in the bacterium.

Abstract: Methods, systems, apparatuses, and computer-readable mediums are described for techniques for supporting telematics-enhanced emergency calls from mobile phones. In some aspects, a method for wireless communication may include establishing, by a user equipment (UE), a personal telematics-enhanced emergency call to a public safety answering point (PSAP), wherein the UE is capable of transmitting telematics data. The method may also include transmitting information that distinguishes the personal telematics-enhanced emergency call from other types of emergency calls.

Abstract: A system for conducting an assay comprises a power source (16), a controller (13) for controlling the assay and a plurality of assay units (14) operatively connected to one another such that the controller can communicate with the assay units and the system is capable of conducting the assay. An assay device comprises a substantially circular body (24) having a plurality of chambers in fluid connection such that fluid can pass between said chambers and a central hub (200) having a sample inlet (202) disposed therein for receiving a sample.

Abstract: Described is a process for producing a mutant bacterium which exhibits improved survival and/or growth under a selected growth condition, the process comprising the steps of: (a) generating a pool of mutant bacteria by transposon mutagenesis with an activating transposon (TnA), wherein the TnA comprises a promoter capable of increasing transcription of a gene at or near its insertion site; (b) growing bacteria from the mutant pool under the selected growth condition and under one or more reference conditions to produce two or more test cultures; and (c) comparing the distribution of TnA insertions between test cultures to identify a first class of genes which are disadvantageous for growth and/or survival under the selected growth condition and a second class of genes which are advantageous for growth and/or survival under the selected growth condition.

Abstract: A method, an apparatus, and a computer program product for wireless communication are provided in connection with improving QoE in RAN congestion. In one example, a communications device is equipped to indicate a quality control indicator (QCI) for each of a plurality of applications that communicate with a RAN over a bearer, receive information regarding modification of the bearer or additional bearers based on the QCIs, and modify the bearer or additional bearers according to the information to achieve a desired QoE for at least one of the plurality of applications. In another example, a RAN is equipped to receive a QCI for each of a plurality of applications related to a bearer from a UE, and modify the bearer or adding additional bearers for communicating with the UE based on the QCI for each of the plurality of applications to improve QoE at the UE.

Abstract: A Home Public Land Mobile Network (HPLMN) or home network immediately accepts a registration requests from “eCall-only” subscribers attempting to register with any Visitor Public Land Mobile Networks (VPLMNs) or roaming network. This avoids unnecessary delays in the establishment of an eCall (emergency call) that might be otherwise introduced by the home network's roaming registration management policy (RRMP) that otherwise would only permit registrations (and subsequent call servicing) by preferred roaming VPLMN partners and automatically reject registrations from non-preferred roaming networks (which may hinder or prevent timely completion of an eCall).

Abstract: Disclosed is a method for identifying an essential gene which serves as an antibiotic target in a bacterium, the method comprising the steps of: (a) generating a pool of mutant bacteria by transposon mutagenesis with an activating transposon (TnA), wherein the TnA comprises a promoter such that transposon insertion into bacterial DNA increases the transcription of a gene at or near the insertion site; (b) growing bacteria from the mutant pool in the presence of different amounts of said antibiotic to produce two or more test cultures; and (c) comparing the distribution of TnA insertions between test cultures to identify a putative essential gene serving as a target of said antibiotic in said bacterium.

Abstract: Disclosed is a method for identifying an essential gene which serves as an antibiotic target in a bacterium, the method comprising the steps of: (a) generating an antibiotic resistant mutant of said bacterium by a method comprising the step of selecting for growth in the presence of said antibiotic to produce an antibiotic resistant mutant clone (AbR mutant); (b) transforming the AbR mutant with: (i) one or more essential genes of said bacterium; and (ii) a transposon which insertionally inactivates bacterial DNA, to produce a pool of transposon mutants which are merodiploid for said one or more essential genes; (c) growing bacteria from the merodiploid pool in the presence of different amounts of said antibiotic to produce two or more test cultures; and (d) comparing the distribution of transposon insertions between test cultures to identify a putative essential gene serving as a target of said antibiotic in said bacterium.

Abstract: Methods, systems, and devices are described for communicating telematics data and metadata. A first device transmits a first signaling message to a second device over a communication session signaling protocol. The first signaling message includes at least a first set of session information related to a communication session between the first device and the second device and a first set of telematics data for the first device. The first device receives a second signaling message from the second device over the communication session signaling protocol. The second signaling message includes metadata based on a content of the first set of telematics data transmitted in the first signaling message.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

Abstract: A Home Public Land Mobile Network (HPLMN) or home network immediately accepts a registration requests from “eCall-only” subscribers attempting to register with any Visitor Public Land Mobile Networks (VPLMNs) or roaming network. This avoids unnecessary delays in the establishment of an eCall (emergency call) that might be otherwise introduced by the home network's roaming registration management policy (RRMP) that otherwise would only permit registrations (and subsequent call servicing) by preferred roaming VPLMN partners and automatically reject registrations from non-preferred roaming networks (which may hinder or prevent timely completion of an eCall).

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionisi?q radiation.